Monday June 4, 4:20 pm Eastern Time
Press Release
SOURCE: Illumina, Inc.
Scott Greer Joins Illumina Board of Directors
SAN DIEGO, June 4 /PRNewswire/ -- Illumina, Inc. (Nasdaq: ILMN - news) announced today the election of R. Scott Greer, Chairman and CEO of Abgenix, Inc., to its Board of Directors. Mr. Greer replaces Charles M. Hartman, General Partner of CW Group, who did not stand for re-election at Illumina's recent annual meeting.
Mr. Greer has served as Chairman of the Board of Abgenix, a biopharmaceutical company, since May 2000 and has been its Chief Executive Officer and a Director since 1996. From 1991 to 1996, Mr. Greer held senior positions with Cell Genesys, a gene therapy company. Those positions included Senior Vice President of Corporate Development and Chief Financial Officer. From 1986 to 1991, Mr. Greer held various positions -- most recently as Director, Corporate Development -- with Genetics Institute, Inc., a biotechnology firm. He is also a Director of CV Therapeutics. Mr. Greer received a B.A. in Economics from Whitman College and an M.B.A. from Harvard University.
Jay Flatley, Illumina President and CEO, commented, ``We are honored that Scott has agreed to join our Board. He brings a solid record of leadership and accomplishment in the life sciences industry and his insight and experience will be a tremendous asset to the Company.''
Illumina (www.illumina.com) is developing next-generation tools that will permit the large-scale analysis of genetic variation and function. The information provided by these analyses will enable the development of personalized medicine, a key goal of genomics and proteomics. The Company's proprietary BeadArray(TM) technology will provide the throughput, cost effectiveness and flexibility necessary to enable researchers in the life sciences and pharmaceutical industries to perform the billions of tests necessary to extract medically valuable information from advances in genomics. This information will correlate genetic variation and gene function with particular disease states, enhancing drug discovery, allowing diseases to be detected earlier and more specifically, and permitting better choices of drugs for individual patients. Illumina's technology will have applicability across a wide variety of industries beyond life sciences and pharmaceuticals, including agriculture, food, chemicals and petrochemicals.
Statements included in this press release that are not historical in nature may be ``forward-looking statements'' within the meaning of the Private Securities Litigation Reform Act of 1995. Any such forward-looking statements involve risks and uncertainties and reflect Illumina's judgment as of the date of this release. Actual events or results may differ from Illumina's expectations as a result of risks and uncertainties identified from time to time in the Company's reports filed with the U.S. Securities and Exchange Commission, including those discussed in ``Factors Affecting Our Operating Results'' and elsewhere in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2000, or in the Company's Form 10-Q for the quarter ended March 31, 2001, or in information disclosed in public conference calls, the date and time of which are released beforehand. Illumina does not plan to update information about its operating results and related expectations until its next earnings release. The Company claims the protection of the Safe Harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.
SOURCE: Illumina, Inc. |
